Podcast appearances and mentions of markus weber

In diesen beiden Folgen ist Markus Weber, Projektleiter der Denkstatt Erzgebirge in Seiffen zu Gast, und spricht über die Zukunft des regionalen Handwerks, insbesondere der Holzspielzeugmacherei. Die Denkstatt Erzgebirge dient als lokales Kreativzentrum, das Tradition und neue Technologien verbindet, um das Handwerk zukunftsorientiert auszurichten und der Abwanderung entgegenzuwirken. Besonderes Augenmerk liegt dabei auf dem Austausch zwischen Design und Handwerk, aber auch auf der Förderung von Gründungsideen, der Zusammenarbeit mit Hochschulen und der Erprobung neuer Techniken für Forschung und Entwicklung innerhalb der regionalen Kreativwirtschaft.

In diesen beiden Folgen ist Markus Weber, Projektleiter der Denkstatt Erzgebirge in Seiffen zu Gast, und spricht über die Zukunft des regionalen Handwerks, insbesondere der Holzspielzeugmacherei. Die Denkstatt Erzgebirge dient als lokales Kreativzentrum, das Tradition und neue Technologien verbindet, um das Handwerk zukunftsorientiert auszurichten und der Abwanderung entgegenzuwirken. Besonderes Augenmerk liegt dabei auf dem Austausch zwischen Design und Handwerk, aber auch auf der Förderung von Gründungsideen, der Zusammenarbeit mit Hochschulen und der Erprobung neuer Techniken für Forschung und Entwicklung innerhalb der regionalen Kreativwirtschaft.

Kretschmer, Svenja www.deutschlandfunk.de, Büchermarkt

In this comprehensive financial presentation, Dr. Markus Weber, President and CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditec AG, review the company's performance for the fiscal year 2023/24. The presentation addresses a slight revenue decline, the achievement of adjusted EBIT forecasts, and strategic initiatives aimed at future growth. Key Financial Highlights for Fiscal Year 2023/24 Revenue Performance Revenue slightly declined compared to the previous fiscal year, primarily due to market challenges in North America and a delayed peak season for refractive surgeries in China. Adjusted EBIT Despite the revenue decline, the company achieved its adjusted EBIT forecast, demonstrating effective cost management and operational efficiency. Strategic Highlights and Market Dynamics Market Challenges Despite weaker demand in North America and a slower-than-expected start to the peak season for refractive surgeries in China, the company's resilience was evident. These challenges, while impacting overall revenue, did not deter our commitment to delivering value to our stakeholders. Cost Management Proactive measures in cost control, particularly in sales and marketing, contributed to maintaining profitability despite market headwinds. Outlook for Fiscal Year 2024/25 Revenue Projections The company anticipates renewed growth in the upcoming fiscal year, with revenue expected to rebound as market conditions improve. EBIT Margin Targets Carl Zeiss Meditec AG maintains its target of achieving an EBIT margin above 20%, focusing on operational efficiency and strategic market positioning. Strategic Initiatives for Future Growth Innovation and Product Development Continued investment in research and development to introduce advanced medical technologies, enhancing the company's competitive edge. Market Expansion Strategic efforts to expand market presence in emerging regions, leveraging partnerships and localized strategies to drive growth. Conclusion Dr. Weber and Mr. Wehmer reaffirm Carl Zeiss Meditec AG's commitment to innovation, operational excellence, and strategic growth initiatives. Despite the challenges faced in the fiscal year 2023/24, the company is poised for renewed growth and remains dedicated to delivering value to its stakeholders, recognizing their importance in our journey. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Live-Gespräch zur Bilanz der Weltklimakonferenz COP29 / Bundeswehr will neue Ausgehuniformen anschaffen / Erste Runde der Präsidentschaftwahl in Rumänien / Weniger Staus oder noch mehr Verkehr? Schweizer Volksabstimmung Autobahnausbau / Herbsttagung der evangelischen Landessynode / Evangelische Christen begehen Totensonntag / Max Verstappen zum vierten Mal Formel-1-Weltmeister / Slalom der Männer in Gurgl // Beiträge von: Simon Plentinger, Markus Weber, Silke Hahne, Kathrin Hondl, Markus Kaiser, Nadja Stempel, Jens Gideon, Andre Siems

Klimagipfel endet nach Verlängerung / Extreme Dürre: Menschen hungern, Tiere verdursten, Ernten verdorren / Bundeswehr will neue Ausgehuniformen anschaffen / Landessynode Herbsttagung 2024 / Vom gefeierten Regisseur zum Nationalisten - Emir Kusturica wird 70 // Beiträge von Janina Schreiber, Stephan Uerberbach, Markus Weber, Markus Kaiser, Oliver Soos // Moderation: Andrea Hermann

Carl Zeiss Meditec AG 9M 2023/24: Key Takeaways Carl Zeiss Meditec AG: Financial Outcomes for First Nine Months of Fiscal Year 2023/24 Carl Zeiss Meditec AG, a pioneer in medical technology, has disclosed its financial outcomes for the first nine months of the fiscal year 2023/24. Despite encountering modest revenue declines, the company's strategic advancements underscore its resilience in navigating the current challenges and seizing future opportunities within the global healthcare market. Revenue and Earnings Overview Over these nine months, Carl Zeiss Meditec reported a revenue of approximately €1,486.5 million, representing a slight decline of 1.5% compared to the previous year's €1,509.6 million. However, when adjusted for currency and acquisition effects, the revenue saw a minimal positive adjustment of 0.1%, with an organic decline of 5%. The earnings before interest and taxes (EBIT) also saw a significant reduction, falling to €162.7 million from the previous year's €244.9 million, resulting in a decrease in the EBIT margin from 16.2% to 10.9%. CEO's Commentary Dr. Markus Weber, CEO of Carl Zeiss Meditec, conveyed a mixed outlook in his commentary. While he acknowledged the underwhelming performance in the third quarter, he also suggested that market recovery might be on the horizon. Signs of stabilization in the order intake for equipment and consumables could indicate a positive shift. The strategic focus for the upcoming fiscal year will include a blend of immediate resilience tactics and more significant medium-term transformation projects across innovation, manufacturing, and commercialization sectors. Strategic Business Units (SBUs) In detail, the strategic business unit (SBU) of Ophthalmology saw a slight revenue dip of 0.8%, closing at €1,143.0 million. Nevertheless, this unit benefited from the consolidation of the newly acquired retinal surgery company DORC, which added €52.7 million to the revenue. The Microsurgery SBU faced a more substantial revenue drop of 3.9%, primarily due to weakened demand in neurosurgery influenced by cautious investment attitudes, especially noticeable in North America. Regional Performance The EMEA (Europe, the Middle East, and Africa) region exhibited strong growth, increasing by 16.1% to €432.2 million, with significant contributions from Italy, Spain, and France. On the contrary, the Americas saw a notable decline of 13.0%, with North American markets showing reluctance in equipment investment. The Asia-Pacific region experienced a modest downturn of 4.1%, although markets like India and Australia contributed positively. Full-Year Forecast and Strategic Initiatives Carl Zeiss Meditec has adjusted its full-year revenue forecast to roughly €2,000 million, incorporating around €100 million from the DORC acquisition. The expected adjusted EBIT ranges between €225 and €275 million. The company focuses on cost control and efficiency improvements, planning savings in the mid to low double-digit million range, excluding impacts from DORC. These initiatives are part of broader transformation efforts to enhance process efficiency and boost productivity, which are anticipated to gradually restore the EBIT margin towards the target of approximately 20%. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using seat11a.com, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Wed, 12 Jun 2024 04:00:00 +0000 https://datensindchefsache.podigee.io/16-16-ki-potenziale-realisieren-erfolgsstrategien-enthullt-mit-markus-weber 15511d9a4f7c3653b1a488f5a7eec6f0 Wie kann Künstliche Intelligenz tatsächlich Ihr Geschäft transformieren? Welche Schritte sind notwendig, um von den Theorien zur praxisnahen Anwendung zu gelangen? In dieser spannenden Episode von „Daten sind Chefsache.“ spricht Feliks Golenko mit dem KI-Experten Markus Weber. Erfahren Sie, wie speziell zugeschnittene KI-Strategien die Effizienz steigern und den Umsatz mittelständischer Unternehmen verdoppeln können. Über Markus Weber: Markus Weber hat sich mit Weber AI Solutions zur Aufgabe gemacht, Künstliche Intelligenz und Automatisierung in Unternehmen in Mittelstand und Industrie zu bringen. Dabei kann er auf 25 Jahre Erfahrung als Ingenieur in der Umsetzung von Technologie- und Transformations-Projekten und die Optimierung von industriellen Prozessen zurückgreifen. Für die Unternehmen seiner Klienten findet er die individuell passenden Lösungen und bringt diese zur erfolgreichen Umsetzung, um damit die Unternehmen fit für die Zukunft mit KI zu machen. Über Feliks Golenko: Als Gründer und CEO von MultiBase verfügt Feliks Golenko über mehr als drei Jahrzehnte Erfahrung in Datenwissenschaft und strategischem Management. Seine Expertise hat zahlreichen Unternehmen dabei geholfen, ihre datengesteuerten Entscheidungsprozesse zu optimieren. Feliks ist ein gefragter Berater, wenn es um Business Intelligence und die Implementierung effektiver Datenvisualisierung geht. Ihre Meinung ist uns wichtig: Ihre Meinung ist uns wichtig: Sind Sie neugierig geworden auf das Thema KI? Haben Sie spezifische Fragen oder Anregungen zu dieser Episode? Wir freuen uns auf Ihren Austausch! Zögern Sie nicht, uns per E-Mail an fgolenko@multibase.de zu kontaktieren. Persönliche Beratung mit Feliks: Interessiert an einer persönlichen Beratung mit Feliks Golenko? Vereinbaren Sie einen Termin und lassen Sie sich dabei helfen, Ihre Datenstrategie zu perfektionieren. Tauchen Sie ein in die Welt der Künstlichen Intelligenz mit Markus Weber und erfahren Sie, wie Sie mit cleveren KI-Anwendungen nicht nur Ihre Prozesse optimieren, sondern auch Ihre Unternehmensziele schneller und effektiver erreichen können. 16 full no Feliks Golenko

Das kleine Mädchen ist seltsam, finden die Eltern und stecken sie in eine Anstalt. Dabei hat sie nur einen Traum. Den Traum vom Fliegen.

Carl Zeiss Meditec Group's H1 2023/24 Financial and Operational Performance Overview In a compelling presentation, the CEO and CFO of Carl Zeiss Meditec Group detailed the company's financial and operational performance for the first half of the fiscal year 2023/24. Addressing a professional audience of stock investors, they revealed a nuanced picture of the company's unwavering resilience and strategic manoeuvres in a challenging economic landscape, instilling a sense of stability and trust. CEO's Overview of Global Economic Impact on Performance The video opens with the CEO, Dr. Markus Weber, summarizing the global economic conditions and their impact on the company. He notes a slight decrease in revenue to €947.2 million, attributing it to factors like geopolitical tensions, which affected our international sales, and supply chain disruptions, which led to production delays. Despite these challenges, strategic business units like Microsurgery showed remarkable growth, signalling robust demand and operational efficiency. CFO's Detailed Financial Analysis The CFO, Justus Felix Wehmer, then takes viewers through a detailed financial analysis, highlighting a decrease in EBIT to €108.2 million and a consolidated profit of €83.9 million. He emphasizes the strategic investments in R&D and marketing, which are crucial for long-term growth despite short-term cost pressures. Strategic Developments and Projections Significant developments, such as the acquisition of DORC BV, are discussed, underscoring Carl Zeiss Meditec's proactive expansion in ophthalmic surgical devices. Both leaders expressed a strong sense of cautious optimism for the second half of the fiscal year, forecasting a recovery in EBIT margins and revenue growth, fuelled by strategic initiatives and market expansions, fostering a positive outlook in the audience. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com

Carl Zeiss Meditec AG Q1 2023/24: Key Takeaways Introduction In this comprehensive video presentation, Carl Zeiss Meditec AG, a leading company in the medical technology sector, showcases its financial results for the first quarter of the fiscal year 2023/24. Dr. Markus Weber, the President and CEO, and the company's CFO provide valuable insights into their financial performance aimed at stock investors and stakeholders. Overview of Financial Performance The video begins with Dr Markus Weber highlighting a slight revenue growth in Q1, reaching €475.0m, a 1.0% increase from the previous year. He notes the normalisation of the order backlog at around €315m and addresses the decline in EBIT to €43.5m, a significant drop from the prior year's €60.3m. The EBIT margin also saw a decrease to 9.2%. Factors Affecting Performance Dr. Weber provides a nuanced explanation of the factors affecting their financial results. He discusses the planned measures to clear the Chinese distribution channel and the impact of currency developments on revenue and earnings. A quarter highlight was the equipment business, which saw good deliveries and improved production times, contributing positively to the financial results. Performance by Strategic Business Units The video presents a detailed analysis of the performance of strategic business units (SBUs). The Ophthalmic Devices SBU experienced a slight decrease in revenue, primarily due to a planned reduction in stock and negative currency effects. In contrast, the Microsurgery SBU showed significant revenue growth, benefiting from a reduction in the high order backlog. Regional Sales Development The presentation covers the heterogeneous sales development across different regions. The EMEA region exhibited substantial revenue growth, while the Americas experienced a decline, mainly due to a decrease in the U.S. market. The APAC region saw a slight decline in revenue, with India and Southeast Asia making positive contributions, but the Chinese market declined. Operating Results and Outlook Dr Weber discusses the operating results, noting a decrease in EBIT as expected, primarily due to a less favourable product mix. The company remains optimistic about the future, expecting revenue growth to align with market trends and a gradual recovery of the EBIT margin in the upcoming year. Conclusion The video concludes with a forward-looking statement from Dr. Weber, expressing confidence in the company's strategic direction and its ability to navigate the challenging macroeconomic environment. The detailed financial analysis provides a clear picture of Carl Zeiss Meditec's current position and prospects, making it an essential watch for investors and analysts in the medical technology industry. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Carl Zeiss Meditec AG FY 2022/23: Key Takeaways Introduction to Carl Zeiss Meditec's Financial Performance In this insightful video presentation, Carl Zeiss Meditec AG, a leader in medical technology, showcases its financial achievements and strategic milestones for the fiscal year 2022/23. Despite a challenging economic environment, the company reported significant revenue growth, led by Dr. Markus Weber, President and CEO. Impressive Revenue Growth Amid Economic Challenges Carl Zeiss Meditec reported a revenue increase to €2,089m, a 9.8% growth from the previous year. The company expanded market shares in its strategic business units (SBUs) – Ophthalmology and Microsurgery – while successfully reducing production and delivery times, demonstrating remarkable resilience and strategic efficiency. Performance Highlights by Business Unit The Ophthalmology SBU saw a 7.3% revenue increase, driven by a reduction in order backlogs and gains in the intraocular lens business. The Microsurgery SBU, on the other hand, recorded an 18.3% revenue growth, outperforming market expectations with enhanced equipment deliveries. Regional Growth and Contributions Carl Zeiss Meditec experienced growth across all regions. The EMEA region saw a 12.7% revenue increase, with significant contributions from Germany, France, and Southern Europe. In the Americas, revenue rose by 17.2%, particularly in the USA and Latin America. Despite challenges in China and Korea, the APAC region contributed positively to overall growth. Financial Analysis: EBIT and Strategic Investments While revenue increased, EBIT declined to €348m, influenced by a less favorable product mix and strategic investments in R&D, especially in digitalization. The EBIT margin was 16.7%, within the forecasted range. Dr. Weber highlighted these investments as crucial for future growth and stabilizing the EBIT margin above 20% in the medium term. Forecast for Fiscal Year 2023/24 For the fiscal year 2023/24, Carl Zeiss Meditec anticipates continued revenue growth, aligning with or surpassing market growth. The forecast considers potential impacts from the Chinese market and product mix adjustments. The company's commitment to research, development, and marketing investments underpins its long-term strategy. Conclusion Dr. Markus Weber's presentation not only underscores Carl Zeiss Meditec's financial resilience but also its strategic foresight in navigating a challenging economic landscape. The company's strong performance in 2022/23 and its optimistic outlook for the future solidify its position as a market leader committed to innovation and growth. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Fachsimpeln mit Markus Weber zum Thema Sportschuhe Es gibt zahlreiche Sportarten, wo man entsprechendes Schuhwerk tragen sollte. Ist das so? Braucht man spezielle Schuhe bzw. Dämpfung, Halt oder Sprengung für die jeweilige Sportart wie Handball, Volleyball, Badminton oder Basketball? Wir wollen dieser Frage auf den Grund gehen und haben uns Markus Weber von Barfußgefühl eingeladen. Markus Wandert, läuft Marathon und spielt Volleyball und das eben nicht in speziell für die Sportart konzipierten Schuhe. Er ist Fan von den Skinners und spielt sowohl barfuß als auch in Skinners Volleyball. Er meint, der Fuß braucht keine technischen Hilfsmittel, um den Sport erfolgreich zu meistern. Zusammen mit Markus stellen wünschen wir uns auch Veränderungen für Schlittschuh und Skischuhe und überlegen, was der Fuß braucht, um in dem notwendigen Schuh Halt zu finden. Was meint ihr dazu? Wie viel Schuh braucht der Fuß im Sport? [Barfussgefühl](https://www.barfussgefuehl.de/) Rabattcode "Barfussgefuehl10" [Facebook Gruppe](https://www.facebook.com/groups/370125074000880) [Barfuss im Pott](https://barfuss-im-pott.de/) [Körper Dynamik](http://koerper-dynamik.de/) [goFree Concepts](https://gofreeconcepts.de/discount/BARFUSSIMPOTT) Affiliate Link mit 5% Rabatt [Knitido](https://www.knitido.de/) 10% Rabatt mit “POTT10” [Freet](https://freetbarefoot.com/de/) Rabattcode „barfuss“ für 10% [Ballop](https://www.ballop-shop.de/barefoot/) Rabattcode „Pott15“ für 15% [Mukishoes](https://mukishoes.com/) Rabattcode "Pottcastmuki" für 10%

Der 85. Jahrestag der Pogromnacht und das Gedenken daran ist unser BR24-Thema des Tages. Dazu hat Markus Weber mit Anna Staroselski gesprochen. Sie ist Sprecherin des deutsch-jüdischen Vereins "Werte-Initiative" und Vize-Präsidentin der "Deutsch-Israelischen Gesellschaft". Außerdem spricht Holger Romann mit unserem Kollegen Daniel Knopp.

In der heutigen Q&A Specialfolge dreht sich alles um das Thema OpenBIM Standards.  Unser Gast Markus Weber, ein Experte auf diesem Gebiet, beantwortet wichtige Fragen rund um die Bedeutung, Vorteile und Anwendungsmöglichkeiten der Open BIM Standards. Erfahre, wie diese Standards die Zusammenarbeit in der Bauindustrie verbessern und zu effizienterem und transparenterem Arbeiten führen können. Wir freuen uns über euer Feedback. Folgt uns gerne auf LinkedIn oder auf Instagram @hslu_digitalconstruction und vergesst nicht ein Like dazulassen. Bis zum nächsten Mal!

Der Militärischer Fünfkämpfer und Hindernisbahnstaffel Vizeweltmeister Markus Weber über seinen sportlichen Werdegang und den komplexen Trainingsaufbau von fünf sehr unterschiedlichen Disziplinen. 

Markus Weber arbeitet beim Kulturzentrum Kreuz und unterstützt Selbstständige, kleine Unternehmen, Vereine und Kulturschaffende im Bereich Öffentlichkeitsarbeit und Marketing. Auch für Moderator Shaggy Schwarz betreut er mehrere Social Media Kanäle, erstellt Webseiten und Werbematerialien. In der neuen Podcast Folge spricht er mit ihm darüber, wie er von Studierendenprotesten zur professionellen Öffentlichkeitsarbeit kam und wie sich die Möglichkeiten für Online-Marketing seither verändert haben.

In this insightful video presentation, Carl Zeiss Meditec AG, a leading medical technology company, reports on its performance during the first half of the fiscal year 2022/23. Despite challenging circumstances, such as the ongoing COVID-19 pandemic and strained global supply chains, the company achieved a remarkable 13.9% growth, generating around €974.5m in revenue. However, this robust revenue growth was offset by a decline in earnings before interest and taxes (EBIT), which dropped to €143.9m from the prior year's €177.3m, primarily due to an unfavourable product mix and rising operational costs.   Notably, the Americas region recorded the most substantial growth, with revenue surging by an impressive 27.6%. The company's strategic business units (SBUs) in Ophthalmology and Microsurgery contributed significantly to this growth. In contrast, the EBIT margin shrank to 14.8% from 20.7% in the previous year, largely due to the pandemic's impact on the Chinese market, increased investment in research and development, higher procurement costs, and rising labour costs.   Despite the decrease in EBIT, the company's CEO, Dr Markus Weber, expresses satisfaction with the company's performance and reaffirms the company's commitment to strategic investments in research and development, supply chain improvements, and shortening delivery times. Looking ahead, Carl Zeiss Meditec AG has consolidated its projections for the fiscal year 2022/23, expecting revenue to increase to around €2.1 billion, with the EBIT margin anticipated to be between 17-20%. T&C: This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Nach der Amoktat in Hamburg bleiben Trauer, Entsetzen und offene Fragen: Wie konnte das geschehen und wie können wir verhindern, dass es wieder passiert? Die Bundesinnenministerin Nancy Faeser will das Waffenrecht verschärfen und fordert unter anderem ein Verbot bestimmter halbautomatischer Schusswaffen. In der Ampelkoalition wird ihr Ansatz kontrovers diskutiert. Hätte so eine Verschärfung den Angriff auf die Zeugen Jehovas in Hamburg vermieden? Müssen wir nicht viel mehr wissen über die, die eine Waffe kaufen wollen, braucht es ein psychologisches Zeugnis? Worin überhaupt liegt die Faszination von Pistolen und Gewehren und wer ist das, der sich für diese Waffen begeistern kann? Darüber sprechen wir mit Dagmar Ellerbrock, Historikerin und Expertin für Waffengeschichte, Martin Rettenberger von der Kriminologischen Zentralstelle (KrimZ), Dietmar Heubrock, der als Sachverständiger den Bundestag zur Reglementierung des Waffenbesitzes beraten hat, und mit Markus Weber, dem Vize-Präsidenten des Hessischen Schützenverbandes.

Drones provide many advantages in agriculture — from collecting data, to applying product, drones can be an asset for growers and agronomists. But learning to fly these nimble flyers and understanding the rules and regulations is key to getting the most out of the tech. Markus Weber, president of Land View, was on hand at... Read More

Der Berg und alle Tiere beschützen die sagenumwobene violette Rose, bis sich ein Wanderer auf den Weg macht, der mit reinem Herzen sehen kann.

Welcome to seat11a, in today's podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: Q3-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Welcome to seat11a, in this podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: H1-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: Seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ----------------------------- ▶️ For business inquiries: info@seat11a.com ----------------------------- ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Ein Mann - ein Schmied. Seine Werke - seine Kinder. Und das perfekte Stück kommt zum Schluss.

Welcome to seat11a, in today's podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: Q1-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ ▶️ In this podcast the CEO and CFO will explain: 00:08 Introduction 00:21 Q1-2021/22: Overview 01:33 Q1-2021/22: Financials 02:22 New Products 02:50 Q1-2021/22: Outlook Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: Seat11a is the next generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ----------------------------- ▶️ For business inquiries: info@seat11a.com ----------------------------- ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Flagstaff County Assistant Ag Fieldman Nick Dunn talks to Markus Weber, president of LandView Drones, about how drones have had an impact on the agricultural industry and how producers can use them as another tool in the toolbox to increase efficiency and return on investment.

Was hat hat Wandsitzen mit erholsamen Schlaf zu tun? Oder: Was hat sportliche Betätigung mit geistiger Gesundheit zu tun? Antworten auf diese Fragen gibt Markus Weber. Der Gründer und Geschäftsführer der V.I.T. GmbH hat schon früh erkannt, dass die richtige Balance von Körper und Geist aus Führungskräften echte Gewinner macht. Shownotes: - Dir gefällt der Podcast? Dann wirst du unsere Audio-Guides für Mitarbeitergespräche lieben: https://begeisterungsland.de/audios/ - Abonniere unseren Newsletter für exklusiven Zugang zu unseren Führungs-Tools: https://begeisterungsland.de/begeisterungsletter/ - Mehr über uns erfährst du hier: https://begeisterungsland.de/unsere-story/ - Folge uns auf Instagram (https://instagram.com/begeisterungsland) und Facebook (https://facebook.com/begeisterungsland/).

1 Jahr Barfuß im PottCast – man was haben wir da schon viel erlebt… Danke an Euch, liebe Hörer, dass Ihr diesen PottCast so lebendig macht. Denn Ihr gebt uns immer neue Idee und Anregungen, worüber wir sprechen können. Heute sprechen wir über ein paar Produkte aus dem Hause Barfußgefühl. Unser lieber Freund Markus Weber begleitet uns auch schon lange vor der Podcast-Zeit und versorgt uns auch immer mal wieder mit Produkten, wo wir unsere fachkundige Meinung zu äußern dürfen. Danke Markus – wir wissen das sehr zu schätzen. Markus verkauft nicht nur gesundes Schuhwerk von diversen Herstellern, sondern hat jetzt in diesem Jahr sogar sein eigenen Modell kreiiert und auf den Markt gebracht: die Barfußgefühl Sandale. Diese vergleichen wir mit den von ihm angebotenen Aborigen Tasmania und Arena, die von Alex seit Jahren getragen werden. Freut euch auf tolle Erkenntnisse, wie die Bequemlichkeit von Alex, meine Bastelaffinität und beeindruckende Daten zu den von uns getesteten Produkten. [Barfußgefühl Weber](https://www.barfussgefuehl.de/) Rabattcode 'barfussimpott-201-81c25itjnyu9' für 5% Rabatt [Facebook Gruppe](https://www.facebook.com/groups/370125074000880) [Barfuss im Pott](https://barfuss-im-pott.de/) [Körper Dynamik](http://koerper-dynamik.de/) [goFree Concepts](https://gofreeconcepts.de/discount/BARFUSSIMPOTT) Affiliate Link mit 5% Rabatt [Knitido](https://www.knitido.de/) 10% Rabatt mit “POTT10” [Vivobarefoot Affiliate](https://www.vivobarefoot.de/?campaign=VIV/AF/ALTO/Gt55zr98ba)

Unterstützt dieses Projekt: https://linktr.ee/purple_ufo Die Webseite und der Podcast von Markus: http://welten-wanderer.com/?fbclid=IwAR0StHrXh88_xe7fPRbeU9W9fDRyQCNVFqqzzpotdvDaC7T7HRCPjWX7rXI --- Send in a voice message: https://anchor.fm/neugierigkontakt/message

In dieser Folge zu Gast sind die Pool-Experten und Hosts des Podcasts „Swimmingpool“, Dietmar Rogg und Markus Weber. Sie sprechen über die Voraussetzungen für den Bau eines Pools, die Planung und die Bauzeit. Aus welchen Bauteilen besteht ein Swimmingpool? Wie viel kosten Bau und Unterhalt? Und wie baut man einen Pool in einen Teich? [Unbezahlte Werbung]

Markus Weber war mit seinem Job als Unternehmensberater nicht mehr zufrieden. Er wollte endlich mal wieder mehr Abenteuer erleben. Mit dem Fahrrad machte er sich dann auf, um im afrikanischen Togo einen Coffee to go zu trinken. Welche Abenteuer Markus auf der monatelangen Fahrt erlebte und ob er da sein Glück gefunden hat, erzählt Markus in diesem Interview.

SWIMMINGPOOL – WIR KLÄREN AUF! DER PODCAST VON POOLEXPERTEN FÜR JEDERMANN. Du träumst vom eigenen Swimmingpool. Du hast einen eigenen Garten oder planst umzuziehen. Wir, Dietmar Rogg und Markus Weber, sind zwei alte Hasen der Schwimmbadbranche und möchten Dir gerne helfen Deinen Traum zu verwirklichen.

Seit dem Wochenende steht die Maskenpflicht in Geschäften zur Debatte. Vera Wolfskämpf berichtet über Stimmen aus Politik und Einzelhandel. Außerdem spricht Markus Weber mit unserem Schweizer Korrespondenten Dietrich-Karl Mäurer, dort gilt seit heute eine Maskenpflicht in öffentlichen Verkehrsmitteln. Moderation: Friederike Breyer.

Herzlich Willkommen zu eurer wöchentlichen Dosis Phantastik! In dieser Woche reden wir über Cover. Zu Gast haben wir hierfür Markus Weber von der Agentur guterpunkt, der seit über 10 Jahren Cover für phantastische Romane gestaltet. Wir reden über Klischees und Veränderungen, über merkwürdige Covertrends und unsere Lieblinge. Genannte Comics: Saga von Brian K. Vaughan, Fiona Staples (Image Comics / in Deutschland erschienen bei Cross Cult) The Witcher - Omnibus (Dark Horse / Einzelbände auf deutsch erschienen bei Panini Verlags GmbH) Sweet Tooth von Jeff Lemire (DC Vertigo / auf deutsch erschienen bei Panini Verlags GmbH) Stjepan Sejic: Harleen (Panini) Genannte Bücher: Ed McDonald: Blackwing (auf deutsch bei Blanvalet: Im Zeichen des Raben) Leigh Bardugo: Gold der Krähen Jackson Ford: Frost Files Rick Yancey: Der Monstrumologe Ben Aaronovitch: Die Flüsse von London Wir auf Twitter: https://twitter.com/Phanta_Brunch Die Agentur guterpunkt: https://www.guter-punkt.de/

Vergangenen Oktober waren wir auf der Frankfurter Buchmesse unterwegs und durften einige Verleger und Verlegerinnen treffen und zu einem kurzen Interview einladen. In dieser Folge: Verlagsleiter Markus Weber vom Moritz Verlag!

Sunday 8th March 2020 Continuing our series ‘Deeper’ Markus Weber spoke about ‘Walk’.     The slides are available here.  

Sunday 23rd February 2020 Markus Weber started our new series ‘Deeper’ with ‘Sit’.     The slides are available here.

Sunday 19th January 2020 Markus Weber (and guests) continued our series ‘Building Together’ with ‘Giving ourselves’.     The slides are available here.

|| Sponsoring: Die Laufsandalen Aborigen Pangea 2.0 wurden mir von barfußgefuehl.de kostenfrei zur Verfügung gestellt. || Wie kam Markus Weber von barfussgefuehl.de zum Laufen, zu Sandalen und zum Barfußlaufen? Welche Aborigen Sandalen wären für mich die richtigen? Wie wähle ich das richtige Modell? Wie wählt man die richtige Größe? Wie stellt man die Aborigen richtig ein? Was muss man am Anfang beachten? Überall dies unterhalten Markus und ich uns in dieser Episode. https://www.barfussgefuehl.de/ Webseite von Markus Weber

Die Experten Talkrunde mit Markus Weber, Mark Steier und mir diskutieren über die Datenschutzgrundverordnung. Hören Sie rein! ▬ Noch mehr Videos ▬▬▬▬▬▬▬▬▬▬▬▬ Abonniere "eBakery": https://tinyurl.com/y9jnvuu9 Alle Videos von "Ali Oukassi": https://tinyurl.com/y9fhjz8y ▬ Social Media ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ ►Facebook “eBakery”: https://www.facebook.com/ebakery.de ►Twitter “eBakery”: https://twitter.com/eBakery_DE ►Twitter “Ali Oukassi”: https://twitter.com/ali_oukassi ►JTL User Community: https://www.facebook.com/groups/JTL.W... ►eCommerce Küche: https://www.facebook.com/groups/ecomm...

Death is a topic we tend to avoid talking about. However one day children will ask: "What happens when we die?"We discovered a book that provides a wide range of unsentimental, helpful ways of talking about death. And we talk to Markus Weber of Moritz Verlag in Frankfurt about what motivated him to publish this book. - Der Tod ist ein Thema, das wir gerne vermeiden. Doch schon als Kinder fragten wir uns: "Und was kommt dann?"So heisst auch ein Bilderbuch, das im Moritz Verlag erschienen ist und herrlich erfrischende Antworten gibt. Wir fragen den Verlagsleiter Markus Weber, was ihn dazu bewogen hat, dieses Buch herauszugeben.

Die neue DSGVO ist eine neue Gesetzordnung die uns alle beschäftigt. Mit Mark Steier und Markus Weber habe wir dieses Thema genauer betrachten wollen. In diesem Podcast erhalten Sie weitere Informationen über die neue alles verändernde Gesetzesvorlage. Ich empfehle Ihnen sich dieses Podcast anzuhören. ▬ Noch mehr Videos ▬▬▬▬▬▬▬▬▬▬▬▬ Abonniere "eBakery": https://tinyurl.com/y9jnvuu9 Alle Videos von "Ali Oukassi": https://tinyurl.com/y9fhjz8y ▬ Social Media ▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬ ►Facebook “eBakery”: https://www.facebook.com/ebakery.de ►Twitter “eBakery”: https://twitter.com/eBakery_DE ►Twitter “Ali Oukassi”: https://twitter.com/ali_oukassi ►JTL User Community: https://www.facebook.com/groups/JTL.W... ►eCommerce Küche: https://www.facebook.com/groups/ecomm...